{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:02:16Z","timestamp":1791925336426,"version":"4.3.4"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":940,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Pharmacosmos"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Iron deficiency (ID) is common in heart failure (HF) and linked with poor prognosis regardless of anaemia. We assessed temporal trends in ID testing, ID prevalence, ID incidence, iron need, and outcomes associated with ID in HF across the ejection fraction (EF) spectrum.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>From the Swedish HF registry, we enrolled 15\u2009197 patients from Region Stockholm with available EF and collected laboratory tests from routine practice. Iron screening improved since 2016 but remained &amp;lt;25% as of 2018. In 1486 patients with iron biomarkers at baseline, the prevalence of ID was 55% (HF with reduced EF 54%; mildly reduced EF 51%; preserved EF 61%). Iron need was \u22651500\u2009mg in 72% of patients. ID was independently associated with higher risk for HF rehospitalizations (incidence rate ratio [IRR] 1.62, 95% confidence interval [CI] 1.13\u20132.31) and with cardiovascular (CV) death or repeated HF hospitalizations (IRR 1.63, 95% CI 1.15\u20132.30) regardless of EF (p-interaction 0.21 and 0.26, respectively), but not with all-cause death, CV death, or first HF hospitalization. Among 96 patients without ID at baseline and with follow-up iron biomarkers, 21% developed ID within 6\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Iron deficiency screening improved over time but is still limitedly implemented, despite being highly prevalent and incident, and independently associated with CV death or HF rehospitalizations regardless of EF. Most patients with ID had an iron need necessitating either repeated administrations of intravenous iron or a preparation permitting &amp;gt;1000\u2009mg doses. These data highlight the need for improved screening for ID in HF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.2879","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T03:05:23Z","timestamp":1682651123000},"page":"1270-1280","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Iron Deficiency in Heart Failure: Screening, Prevalence, Incidence and Outcome Data from the Swedish Heart Failure Registry and the Stockholm CREAtinine Measurements Collaborative Project"],"prefix":"10.1093","volume":"25","author":[{"given":"Felix","family":"Lindberg","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars H.","family":"Lund","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Karolinska Institutet , Stockholm ,","place":["Sweden"]},{"name":"Heart and Vascular and Neurology Theme, Karolinska University Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Benson","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Linde","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Orsini","sequence":"additional","affiliation":[{"name":"Department of Global Public Health, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jesus","family":"Carrero","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Karolinska Institutet , Stockholm ,","place":["Sweden"]},{"name":"Division of Nephrology, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7732-0887","authenticated-orcid":false,"given":"Gianluigi","family":"Savarese","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Karolinska Institutet , Stockholm ,","place":["Sweden"]},{"name":"Heart and Vascular and Neurology Theme, Karolinska University Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"2026010913100283100_ejhf2879-bib-0001","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/eurheartj\/ehs224","article-title":"Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives","volume":"34","author":"Jankowska","year":"2013","journal-title":"Eur Heart J"},{"key":"2026010913100283100_ejhf2879-bib-0002","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"key":"2026010913100283100_ejhf2879-bib-0003","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"key":"2026010913100283100_ejhf2879-bib-0004","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"2026010913100283100_ejhf2879-bib-0005","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","article-title":"Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial","volume":"400","author":"Kalra","year":"2022","journal-title":"Lancet"},{"key":"2026010913100283100_ejhf2879-bib-0006","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913100283100_ejhf2879-bib-0007","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ejhf.1182","article-title":"Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Rregistry","volume":"20","author":"Savarese","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026010913100283100_ejhf2879-bib-0008","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s10741-021-10077-x","article-title":"Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction","volume":"27","author":"Greene","year":"2021","journal-title":"Heart Fail Rev"},{"key":"2026010913100283100_ejhf2879-bib-0009","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/eurjhf\/hfp175","article-title":"Heart failure registry: a valuable tool for improving the management of patients with heart failure","volume":"12","author":"Jonsson","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026010913100283100_ejhf2879-bib-0010","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/03009734.2018.1490831","article-title":"The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure","volume":"124","author":"Savarese","year":"2019","journal-title":"Ups J Med Sci"},{"key":"2026010913100283100_ejhf2879-bib-0011","volume-title":"RiksSvikt 2021 \u00c5rsrapport","author":"UCR"},{"key":"2026010913100283100_ejhf2879-bib-0012","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/joim.13418","article-title":"The Stockholm CREAtinine Measurements (SCREAM) project: fostering improvements in chronic kidney disease care","volume":"291","author":"Carrero","year":"2022","journal-title":"J Intern Med"},{"key":"2026010913100283100_ejhf2879-bib-0013","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/ehf2.12006","article-title":"Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency","volume":"1","author":"Ponikowski","year":"2014","journal-title":"ESC Heart Fail"},{"key":"2026010913100283100_ejhf2879-bib-0014","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1080\/00015385.2019.1625554","article-title":"The importance of dose optimisation in the treatment of iron deficiency in heart failure","volume":"75","author":"Martens","year":"2020","journal-title":"Acta Cardiol"},{"key":"2026010913100283100_ejhf2879-bib-0015","first-page":"1","article-title":"Mice: multivariate imputation by chained equations in R","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Softw"},{"key":"2026010913100283100_ejhf2879-bib-0016","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2026010913100283100_ejhf2879-bib-0017","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"2026010913100283100_ejhf2879-bib-0018","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/eurheartj\/ehq158","article-title":"Iron deficiency: an ominous sign in patients with systolic chronic heart failure","volume":"31","author":"Jankowska","year":"2010","journal-title":"Eur Heart J"},{"key":"2026010913100283100_ejhf2879-bib-0019","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s00392-016-1073-y","article-title":"Prevalence and clinical impact of iron deficiency and anaemia among outpatients with chronic heart failure: the PrEP registry","volume":"106","author":"von Haehling","year":"2017","journal-title":"Clin Res Cardiol"},{"key":"2026010913100283100_ejhf2879-bib-0020","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.amjcard.2016.08.081","article-title":"Usefulness of iron deficiency correction in management of patients with heart failure [from the Registry Analysis of Iron Deficiency-Heart Failure (RAID-HF) Registry]","volume":"118","author":"Wienbergen","year":"2016","journal-title":"Am J Cardiol"},{"key":"2026010913100283100_ejhf2879-bib-0021","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1002\/ejhf.2338","article-title":"Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry","volume":"23","author":"Becher","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026010913100283100_ejhf2879-bib-0022","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ahj.2013.01.017","article-title":"Iron deficiency in chronic heart failure: an international pooled analysis","volume":"165","author":"Klip","year":"2013","journal-title":"Am Heart J"},{"key":"2026010913100283100_ejhf2879-bib-0023","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/ehf2.13850","article-title":"Iron deficiency in heart failure patients: the French CARENFER prospective study","volume":"9","author":"Cohen-Solal","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026010913100283100_ejhf2879-bib-0024","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00392-018-1344-x","article-title":"Iron deficiency in patients with heart failure with preserved ejection fraction and its association with reduced exercise capacity, muscle strength and quality of life","volume":"108","author":"Bekfani","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"2026010913100283100_ejhf2879-bib-0025","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/ejhf.139","article-title":"High prevalence of iron deficiency in patients with acute decompensated heart failure","volume":"16","author":"Cohen-Solal","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026010913100283100_ejhf2879-bib-0026","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2019-001012","article-title":"Iron deficiency in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"6","author":"Beale","year":"2019","journal-title":"Open Heart"},{"key":"2026010913100283100_ejhf2879-bib-0027","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/00015385.2017.1351239","article-title":"Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction","volume":"73","author":"Martens","year":"2018","journal-title":"Acta Cardiol"},{"key":"2026010913100283100_ejhf2879-bib-0028","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jacc.2021.11.039","article-title":"Criteria for iron deficiency in patients with heart failure","volume":"79","author":"Masini","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026010913100283100_ejhf2879-bib-0029","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41569-021-00605-5","article-title":"Heart failure with mid-range or mildly reduced ejection fraction","volume":"19","author":"Savarese","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"2026010913100283100_ejhf2879-bib-0030","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/ehf2.13245","article-title":"Diagnosis and treatment of iron deficiency in heart failure: OFICSel study by the French Heart Failure Working Group","volume":"8","author":"Pezel","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026010913100283100_ejhf2879-bib-0031","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/ejhf.473","article-title":"Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials","volume":"18","author":"Jankowska","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026010913100283100_ejhf2879-bib-0032","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.jacc.2011.04.040","article-title":"Disordered iron homeostasis in chronic heart failure prevalence, predictors, and relation to anemia, exercise capacity, and survival","volume":"58","author":"Okonko","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026010913100283100_ejhf2879-bib-0033","author":"ClinicalTrials.gov."},{"key":"2026010913100283100_ejhf2879-bib-0034","volume-title":"Effects of Iron Therapy in Heart Failure With Preserved Ejection Fraction and Iron Deficiency (PREFER-HF)","author":"ClinicalTrials.gov"},{"key":"2026010913100283100_ejhf2879-bib-0035","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/ejhf.813","article-title":"Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry","volume":"19","author":"Chioncel","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026010913100283100_ejhf2879-bib-0036","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1002\/ehf2.13617","article-title":"Impact of change in iron status over time on clinical outcomes in heart failure according to ejection fraction phenotype","volume":"8","author":"Fitzsimons","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026010913100283100_ejhf2879-bib-0037","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/ejhf.2251","article-title":"Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure","volume":"24","author":"Graham","year":"2022","journal-title":"Eur J Heart Fail"}],"updated-by":[{"DOI":"10.1002\/ejhf.3344","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T00:00:00Z","timestamp":1719100800000}}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/8\/1270\/65494454\/eurjhf_25_8_1270.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/8\/1270\/65494454\/eurjhf_25_8_1270.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:12:25Z","timestamp":1767982345000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/25\/8\/1270\/8341858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":37,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,5,10]]},"published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.2879","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8]]},"published":{"date-parts":[[2023,5,10]]},"assertion":[{"value":"2022-12-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}